MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth

The Johnson & Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United Kingdom, and as eXeX launches Canopus Command, the first portal to give hospital leadership a live operational view into step-by-step execution of every surgical case. ORLANDO, Fla.

PRNewsWire • 16 hours ago

Orthofix to Participate in Upcoming Investor Conferences

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Orthofix will participate in the following investor conferences: Needham Virtual MedTech & Diagnostics 1x1 Conference - Virtual, August 10, 2026, 1x1 Meetings Canaccord Genuity's 46th Annual Growth Conference - Boston, August 12, 2026, Fireside Chat Time: 9:30 am Eastern Time Interested parties can access the live and archived webcast of the Canaccord Ge.

Business Wire • Jul 20, 2026

Orthofix to Report Second Quarter 2026 Financial Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referenc.

Business Wire • Jul 15, 2026

Orthofix (OFIX) Moves 5.1% Higher: Will This Strength Last?

Orthofix (OFIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Jun 29, 2026

Orthofix Medical Inc. (OFIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Orthofix Medical Inc. (OFIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 8, 2026

Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Jun 5, 2026

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Orthofix Medical Inc. (NASDAQ: OFIX)

NEW YORK, May 26, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Orthofix Medical Inc. (NASDAQ: OFIX) on behalf of the company's shareholders. The investigation seeks to determine whether Orthofix Medical's directors breached their fiduciary duties in connection with recent corporate actions.

PRNewsWire • May 26, 2026

Orthofix Expands Pediatric Limb Reconstruction Portfolio with New FITBONE™ Innovation at POSNA 2026 Annual Meeting

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced new pediatric limb reconstruction innovations that expand treatment options for pediatric and small stature patients. The Company will highlight these advances at the Pediatric Orthopedic Society of North America (POSNA) 2026 Annual Meeting, which takes place May 6-8, 2026, at the Rosen Shingle Creek Hotel in Orlando, Florida. At POSNA 2026, Orthofix will showcas.

Business Wire • May 6, 2026

Orthofix Medical Inc. (OFIX) Q1 2026 Earnings Call Transcript

Orthofix Medical Inc. (OFIX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 5, 2026

Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ pr.

Business Wire • May 5, 2026